Most of us may know someone who is living with or has battled cancer. It is a disease that often lasts a lifetime.
The Georgia Cancer Research Center is developing a new option to traditional chemotherapy.
For those living with the disease, treatment becomes a part of their life, and for some, it goes on for many years.
Dr. Esteban Celis and Dr. Sharad Ghamande are treating select patients with a new alternative.
According to one of their patients, she sees results better than standard treatment protocol.
Celis has been studying cancer vaccines for years. After several experiments, he and his team came up with a new option they believe will benefit cancer patients better than chemotherapy.
“He saw this combination offer more in the lab then the current standard of care,” said Ghamande. “That’s it how it became a clinical trial.”
The Gynecologic Oncology specialist told NewsChannel 6 reporter, Devin Johnson, it’s a combination of the standard immunotherapy and a new drug through research from the cancer center.
“Together they are much better then they are separate,” said Ghamande This new molecule expands the range of how many people can benefit from the checkpoint antibody immunity.”
One patient travels here from Atlanta every three weeks for endometrial cancer treatment; a type of uterine cancer.
She says she agreed to be tested for the clinical trials after her doctor recommended it.
“Whatever they recommend I trust in them to know what they were doing to do the right thing,” said Annie Troup.
Eighteen cycles later Troup has received this treatment the longest with the new therapy. She says she has better results than she did with standard chemo.
“I hope and pray everything keeps working out good,” explained Troup. “Also, I’ll be able to help somebody as I’m being helped.”
Even though chemotherapy is here to stay, both Troup and Dr. Ghamande hope the clinical trials can be a resource to save millions of cancer patients.
“It would be a blessing to them and me to knowing that, what I went through they can do the same thing,” said Troup.
The clinical trials have completed phase one. Dr. Ghamande told Devin the team is ready to move on to step two.
Also, the new theory is an option for all cancers.